L-asparaginase: clinical, biochemical, pharmacological, and immunological studies.
D000293:Adolescent; D000328:Adult; D000917:Antibody Formation; D000970:Antineoplastic Agents / Q000627:therapeutic use*; D001215:Asparaginase / Q000009:adverse effects / Q000378:metabolism / Q000627:therapeutic use*; D001216:Asparagine / Q000378:metabolism; D001856:Bone Marrow Examination; D002648:Child; D002675:Child, Preschool; D003561:Cytarabine / Q000627:therapeutic use; D004342:Drug Hypersensitivity; D005260:Female; D006801:Humans; D007938:Leukemia / Q000188:drug therapy*; D007945:Leukemia, Lymphoid / Q000188:drug therapy / Q000276:immunology; D007948:Leukemia, Monocytic, Acute / Q000188:drug therapy / Q000276:immunology; D015470:Leukemia, Myeloid, Acute / Q000188:drug therapy / Q000276:immunology; D008297:Male; D008875:Middle Aged; D011241:Prednisone / Q000627:therapeutic use; D012075:Remission, Spontaneous
D000970:Antineoplastic Agents; D003561:Cytarabine; D001216:Asparagine; D001215:Asparaginase; D011241:Prednisone